Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.
Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.